Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy

Show full item record



Permalink

http://hdl.handle.net/10138/217894

Citation

Vaha-Koskela , M , Tahtinen , S , Gronberg-Vaha-Koskela , S , Taipale , K , Saha , D , Merisalo-Soikkeli , M , Ahonen , M , Rouvinen-Lagerstrom , N , Hirvinen , M , Veckman , V , Matikainen , S , Zhao , F , Pakarinen , P , Salo , J , Kanerva , A , Cerullo , V & Hemminki , A 2015 , ' Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy ' , Molecular Therapy - Oncolytics , vol. 2 , 14006 . https://doi.org/10.1038/mto.2014.6

Title: Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy
Author: Vaha-Koskela, Markus; Tahtinen, Siri; Gronberg-Vaha-Koskela, Susanna; Taipale, Kristian; Saha, Dipongkor; Merisalo-Soikkeli, Maiju; Ahonen, Marko; Rouvinen-Lagerstrom, Noora; Hirvinen, Mari; Veckman, Ville; Matikainen, Sampsa; Zhao, Fang; Pakarinen, Paivi; Salo, Jarmo; Kanerva, Anna; Cerullo, Vincenzo; Hemminki, Akseli
Contributor: University of Helsinki, Institute of Biotechnology
University of Helsinki, Faculty of Pharmacy
University of Helsinki, Haartman Institute (-2014)
University of Helsinki, Faculty of Pharmacy
University of Helsinki, Haartman Institute (-2014)
University of Helsinki, Department of Obstetrics and Gynecology
University of Helsinki, Clinicum
University of Helsinki, Faculty of Pharmacy
University of Helsinki, Medicum
Date: 2015-01-07
Language: eng
Number of pages: 9
Belongs to series: Molecular Therapy - Oncolytics
ISSN: 2372-7705
URI: http://hdl.handle.net/10138/217894
Abstract: Successful cancer control relies on overcoming resistance to cell death and on activation of host antitumor immunity. Oncolytic viruses are particularly attractive in this regard, as they lyse infected tumor cells and trigger robust immune responses during the infection. However, repeated injections of the same virus promote antiviral rather than antitumor immunity and tumors may mount innate antiviral defenses to restrict oncolytic virus replication. In this article, we have explored if alternating the therapy virus could circumvent these problems. We demonstrate in two virus-resistant animal models a substantial delay in antiviral immune- and innate cellular response induction by alternating injections of two immunologically distinct oncolytic viruses, adenovirus, and vaccinia virus. Our results are in support of clinical development of heterologous adeno-/vaccinia virus therapy of cancer.
Subject: SEMLIKI-FOREST-VIRUS
VACCINIA VIRUS
ONCOLYTIC ADENOVIRUS
IMMUNE-RESPONSE
GENE DELIVERY
IN-VIVO
VECTORS
CANCER
INDUCTION
PATHWAYS
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S2372770516300018_main.pdf 550.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record